Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
- Registration Number
- NCT00676143
- Lead Sponsor
- Pfizer
- Brief Summary
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 1100
- Diagnosis of probable AD, with MMSE score of 16-26, and brain MRI consistent with the diagnosis of AD
- Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.
- Caregiver will participate and be able to attend clinic visits with patient.
- Significant neurological disease other than AD, or a major psychiatric disorder
- Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)
- Woman of childbearing potential
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Bapineuzumab 0.5 mg/kg bapineuzumab - Placebo placebo -
- Primary Outcome Measures
Name Time Method Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)/11 Subscale Total Score at Week 78 Baseline and 78 weeks The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4) constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8) remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension.
This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced.
The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 78 Baseline and 78 weeks The DAD measures instrumental and basic activities of daily living in participants with Alzheimer's Disease (AD). The DAD is administered to the participants'caregiver in the form of an interview. This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced by the participant.
This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item can be scored as 1 = yes, 0 = no, non applicable = NA. A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores indicate better function; a positive change from baseline indicates an improvement.
- Secondary Outcome Measures
Name Time Method Change From Baseline in Brain Amyloid Burden at Week 71 Baseline and 71 weeks Brain amyloid burden as imaged by 11C-Pittsburgh compound B (PIB) positron emission tomography (PET). The latter is a semi-quantitative measure of the extent of fibrillar amyloid in the brain. PIB PET measurements were made in cortical regions found to have the highest burden of fibrillar amyloid at autopsy in participants diagnosed as having Alzheimer's pathology, and also regions reported to have the highest average retention of PIB signal in previous PET studies enrolling participants with probable AD. This parameter reflects overall brain amyloid deposition as indexed by imaging. The change from baseline was measured as average standard uptake value ratio (SUVr) in prespecified regions of interest (ROI) assessed by PIB PET imaging in a subset of participants.
Change From Baseline in Cerebrospinal Fluid (CSF) Phospho-tau Levels at Week 71 Baseline and 71 Weeks Biomarkers CSF phospho-tau is an indicator of neuronal injury and neurodegeneration. An elevation in levels of tau, as well as specific p-tau species, is thought to be a marker for progressive cellular degeneration in AD. Accordingly, a reduction from baseline in levels of CSF tau in participants who received bapineuzumab compared with participants who received placebo may be indicative of a reduction in neuronal loss in participants treated with bapineuzumab.
Change From Baseline in Brain Volume, as Assessed by Magnetic Resonance Imaging Brain Boundary Shift Integral (MRI BBSI), at Week 71 Baseline and 71 Weeks Cerebral atrophy correlates closely with the gradual cognitive decline in AD and can be visualized by MRI. The BBSI technique involves positional matching of serial 3-dimensional MRI brain images, such that brain MRI-image volumes were first registered and then subtracted from each other. Atrophy rates would generally be expected to be lower if the underlying disease was attenuated by effective treatment.
Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78 Week 39 to Week 78 Treatment differences are estimated using least-squares (LS) means with factor levels weighted according to overall analysis population proportions. ADAS-Cog/11 total score range is 0 (least impairment) to 70 (most impairment); a negative treatment difference (bapineuzumab minus placebo) favors bapineuzumab. Within the MMRMs for ADAS-Cog/11 described for the primary analyses, linear contrasts were formed to test increasing trend of the differences between bapineuzumab and placebo from Week 39 (the 9-month visit) through Week 78 (the 18 -month visit) for each variable, which is equivalent to testing a positive slope of the differences between each bapineuzumab dose group and placebo from Week 39 through Week 78. Results are from a restricted maximum likelihood (REML)-based mixed model for MMRM.
Divergence of Effect on the DAD Total Scores From Week 39 to Week 78 Week 39 to Week 78 Treatment differences are estimated using least-squares (LS) means with factor levels weighted according to overall analysis population proportions. DAD total score range is 0 to 100; a positive treatment difference (bapineuzumab minus placebo) favors bapineuzumab. Within the MMRMs for ADAS-Cog/11 described for the primary analyses, linear contrasts were formed to test increasing trend of the differences between bapineuzumab and placebo from Week 39 (the 9-month visit) through Week 78 (the 18 -month visit) for each variable, which is equivalent to testing a positive slope of the differences between each bapineuzumab dose group and placebo from Week 39 through Week 78. Results are from a restricted maximum likelihood (REML)-based mixed model for MMRM.
Time to First Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan) Baseline and 78 Weeks The time to first median placebo deterioration, defined as the first time a participant experienced an increase (worsening) from baseline in ADAS-Cog/11 total score greater than or equal to the median worsening observed at Week 78 in the placebo group. The Kaplan Meier estimate of median time to first median placebo deterioration was presented.
Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan) Baseline and 78 Weeks The time to first clinically meaningful deterioration was defined as the first time a participant experienced an increase (worsening) from baseline in ADAS-Cog/11 total score of \>=7.
Time to First Median Placebo Deterioration on DAD Total Score (EU Analysis Plan) Baseline and 78 Weeks The time to first median placebo deterioration was defined as the first time a participant experienced a decrease (worsening) in DAD total score greater than or equal to the median worsening at Week 78 in the placebo group.
Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis) Baseline and 78 Weeks The time to first clinically meaningful deterioration was defined as the first time a participant experienced a decrease (worsening) from baseline in DAD total score of \>=12.
Change From Baseline in Dependence Scale Total Score at Week 78 Baseline and 78 Weeks The Dependence Scale (DS) is a 13-item, caregiver-rated instrument for determining the amount of support required by a participant with AD. The DS total score ranges from 0 to 15, with higher scores indicating more need for assistance. The DS was administered as an interview to the caregiver at scheduled study visits.
Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (EU Analysis Plan) Baseline and 78 Weeks Percentage of participants with worsening from baseline to Week 78 in ADAS-Cog/11 total score of ≤0, ≤3, and ≤7 points were reported. In order to calculate time to first median placebo deterioration in ADAS-Cog/11, the median change from baseline to Week 78 among the placebo participants of the mITT analysis population were determined. The median changes were used as the cutpoints for determining "deterioration" for Alzheimer's disease participants in the study. If the median change from baseline to Week 78 in the ADAS-Cog/11 total score among the placebo participants of the mITT Analysis Population is 7 points, then the first median placebo deterioration is the first time where there is a worsening on the ADAS-Cog/11 total score of 7 points or more and the worsening is confirmed by the ADAS-Cog/11 assessment at the next non-missing visit.
Percentage of Responders for ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan) Baseline and 78 Weeks Percentage of participants whose increase (worsening) from baseline to Week 78 in ADAS-Cog/11 total score was \<7.
Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (EU Analysis Plan) Baseline and 78 Weeks Percentage of participants whose decrease (worsening) from baseline to Week 78 in DAD total score of ≤ 0, ≤ 6, and ≤ 12 points. In order to calculate time to first median placebo deterioration in DAD, the median change from baseline to Week 78 among the placebo participants of the mITT analysis population were determined. The median changes were used as the cutpoints for determining "deterioration" for Alzheimer's disease participants in the study. If the median change from baseline to Week 78 in the DAD total score among the placebo participants of the mITT Analysis Population is 7 points, then the first median placebo deterioration is the first time where there is a worsening on the DAD total score of 7 points or more and the worsening is confirmed by the DAD assessment at the next non-missing visit.
Percentage of Responders for DAD Total Score at Week 78 (US Analysis Plan) Baseline and 78 Weeks Percentage of participants whose decrease (worsening) from baseline to Week 78 in DAD total score was \<12.
Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78 Baseline and 78 Weeks The CDR-SOB is a global clinical staging instrument that sums 6 clinical ratings: 1) memory, 2) orientation, 3) judgment and problem solving, 4) involvement in community affairs, 5) home and hobbies, and 6) personal care based on the Clinical Dementia Rating Scale (CDR) interview. The CDR includes discussions with the participant and caregiver using a structured format. This scale had to be administered by a trained and certified global rater who did not have access to any information regarding adverse events experienced by the participant. CDR-SOB total score range is 0 (least impairment) to 18 (most impairment); a negative change from baseline indicates an improvement.
Trial Locations
- Locations (278)
UPENN Clinical and Transitional Research Center
🇺🇸Philadelphia, Pennsylvania, United States
Texas Neurology, P.A.
🇺🇸Dallas, Texas, United States
Compass Research, LLC
🇺🇸Orlando, Florida, United States
Lake Charles Clinical Trials
🇺🇸Lake Charles, Louisiana, United States
Clinical Trials, Inc.
🇺🇸Little Rock, Arkansas, United States
Palm Beach Neurological Center
🇺🇸Palm Beach Gardens, Florida, United States
Alexian Brothers Medical Center
🇺🇸Elk Grove Village, Illinois, United States
Hôpital Cimiez C.M.R.R.
🇫🇷Nice, France
Neurostudies Inc
🇺🇸Port Charlotte, Florida, United States
Roskamp Institute
🇺🇸Sarasota, Florida, United States
Hattiesburg Clinic
🇺🇸Hattiesburg, Mississippi, United States
Carolina Neuropsychological Services, Inc
🇺🇸Raleigh, North Carolina, United States
AC Institute, Incorporated
🇺🇸Carson, California, United States
Alpine Clinical Research Center, Inc.
🇺🇸Boulder, Colorado, United States
Norman S. Werdiger, MD
🇺🇸New Haven, Connecticut, United States
Brain Matters Research
🇺🇸Delray Beach, Florida, United States
University of South Florida
🇺🇸Tampa, Florida, United States
Center for Healthy Aging
🇺🇸Greenwich, Connecticut, United States
Neurostudies.net
🇺🇸Decatur, Georgia, United States
Dekalb Neurology Associates, LLC/NeuroStudies.net, LLC
🇺🇸Decatur, Georgia, United States
Hospital of the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Associated Neurologists of Southern Connecticut, P.C.
🇺🇸Fairfield, Connecticut, United States
Wake Radiology Associates
🇺🇸Raleigh, North Carolina, United States
Bendheim Cancer Center
🇺🇸Greenwich, Connecticut, United States
Moshe Hasbani, MD
🇺🇸New Haven, Connecticut, United States
Shields MRI
🇺🇸Dartmouth, Massachusetts, United States
Neuroscience Research of the Berkshires
🇺🇸Pittsfield, Massachusetts, United States
Thomas Jefferson University Hospital
🇺🇸Philadelphia, Pennsylvania, United States
Pharmcare USA
🇺🇸Edison, New Jersey, United States
Healthsouth Blue Ridge Surgery Center
🇺🇸Raleigh, North Carolina, United States
Memorial Medical Center
🇺🇸Springfield, Illinois, United States
Memory Enhancement Center of America, Inc.
🇺🇸Eatontown, New Jersey, United States
Neurological Care of Central New York
🇺🇸Liverpool, New York, United States
Raleigh Neurology Associates
🇺🇸Raleigh, North Carolina, United States
The Clinical Trial Center, LLC
🇺🇸Jenkintown, Pennsylvania, United States
The Memory Clinic
🇳🇿Auckland, NZ, New Zealand
Butler Hospital
🇺🇸Providence, Rhode Island, United States
Medical University of South Carolina Hospitals and Clinics
🇺🇸Charleston, South Carolina, United States
ZNA Middelheim
🇧🇪Antwerpen, Belgium
H.-Hartziekenhuis Roeselare-Menen
🇧🇪Roeselare, Belgium
CHU de Caen
🇫🇷Caen, France
Gosford Hospital
🇦🇺Gosford, New South Wales, Australia
Springfield Neurology Associates, LLC
🇺🇸Springfield, Massachusetts, United States
University of Michigan Hospital and Health System
🇺🇸Ann Arbor, Michigan, United States
Michigan State University
🇺🇸East Lansing, Michigan, United States
University of Wisconsin Hospitals and Clinics
🇺🇸Madison, Wisconsin, United States
Royal Adelaide Hospital
🇦🇺Adelaide, South Australia, Australia
Simpson's Pharmacy
🇺🇸Pawtucket, Rhode Island, United States
Abington Memorial Hosptial
🇺🇸Abington, Pennsylvania, United States
Ohio State University Imaging@Martha Moorehouse
🇺🇸Columbs, Ohio, United States
University of Michigan Health System
🇺🇸Ann Arbor, Michigan, United States
Abington Neurological Associates
🇺🇸Willow Grove, Pennsylvania, United States
The Center for Pharmaceutical Research P.C.
🇺🇸Kansas City, Missouri, United States
University of Wisconsin School of Medicine and Public Health
🇺🇸Madison, Wisconsin, United States
Rhode Island Mood and Memory Research Institute
🇺🇸East Providence, Rhode Island, United States
Hornsby Kuringai Hospital
🇦🇺Hornsby, New South Wales, Australia
Cemic University Hospital
🇦🇷Buenos Aires, Argentina
Waisman Center (PET only)
🇺🇸Madison, Wisconsin, United States
Investigational New Drug Services
🇺🇸Philadelphia, Pennsylvania, United States
University Hospital Center Zagreb
🇭🇷Zagreb, Croatia
Dr. Michael Gabe (Clinic)
🇺🇸Silverton, Oregon, United States
Instituto Kremer
🇦🇷Cordoba, Argentina
Andorra MRI of Flourtown
🇺🇸Flourtown, Pennsylvania, United States
MUSC
🇺🇸Charleston, South Carolina, United States
CHU Hôpital Gui de Chaulliac
🇫🇷Montpellier, France
The Pharmacy
🇺🇸Bennington, Vermont, United States
Gosford Hospital; Pharmacy Dept
🇦🇺Gosford, New South Wales, Australia
Dipartimento di Neuroscienze,
🇮🇹Catania, Italy
CHU de Dijon
🇫🇷Dijon, France
Nagoya City University Hospital
🇯🇵Nagoya, Aichi,, Japan
Osaka University Hospital
🇯🇵Osaka, Japan
CDAMS Ballarat Base Hospital
🇦🇺Ballarat, Victoria, Australia
Hôpital la Timone
🇫🇷Marseille, France
Heidelberg Repatriation Hospital
🇦🇺West Heidelberg, Victoria, Australia
Hôpital Pitié-Salpétrière
🇫🇷Paris, France
Hopital neurologique du Pr A. Vighetto
🇫🇷Bron, France
Instituto Medico Congreso
🇦🇷Buenos Aires, Argentina
SZ Sued - Kaiser-Franz-Josef-Spital
🇦🇹Wien, Austria
University of Turku / CRST
🇫🇮Turku, Finland
Cliniques Universitaires St Luc
🇧🇪Brussels, Belgium
Universitair Ziekenhuis Antwerpen
🇧🇪Edegem, Belgium
Universitair Ziekenhuis Gasthuisberg
🇧🇪Leuven, Belgium
Wm S. Middleton Memorial Veterans Hospital
🇺🇸Madison, Wisconsin, United States
CHU Pellegrin
🇫🇷Bordeaux Cedex, France
The Queen Elizabeth Hospital
🇦🇺Woodville South, South Australia, Australia
Hospital Italiano de Buenos Aires
🇦🇷Buenos Aires, Argentina
Medizinische Universitaet Graz
🇦🇹Graz, Austria
Allg. Krankenhaus der Stadt Wien
🇦🇹Wien, Austria
Az. St. Jan Ruddershove 35
🇧🇪Brugge, Belgium
A.O. Umberto I
🇮🇹Ancona, Italy
Service d'Imagerie Medicale
🇫🇷Nice, France
CHU Nord - Hôpital Guillaume et René Laënnec
🇫🇷Nantes - Saint Herblain, France
Hospital Jean Bernard CIC
🇫🇷Poitiers, France
Universitaetsklinikum Dresden
🇩🇪Dresden, Germany
Klinikum der Albert-Ludwigs-Universitaet Freiburg
🇩🇪Freiburg, Germany
Hôpitaux Civils de Colmar
🇫🇷Colmar, France
NZOZ Dom Suer Ryder, Pallmed Sp. z o.o.
🇵🇱Bydgoszcz, Poland
Amphia Ziekenhuis
🇳🇱Breda, Noord Brabant, Netherlands
Groupe Hospitalier Broca-La Rochefoucauld
🇫🇷Paris, France
Denmar Clinic
🇿🇦Pretoria, Gauteng, South Africa
Clinica Neurologica - II Neurologia
🇮🇹Brescia, Italy
Unita' Operativa Complessa di Neurologia
🇮🇹Catania, Italy
C.H.U de Reims
🇫🇷Reims, France
Universitaetsklinikum Ulm
🇩🇪Ulm, Germany
CHU de Rennes
🇫🇷Rennes Cedex, France
Yachiyo Hospital
🇯🇵Aichi, Japan
Nishi-Kobe Medical Center
🇯🇵Hyogo, Japan
National Hospital Organization Kokura Medical Center
🇯🇵Fukuoka, Japan
St. Josef-Klinikum
🇩🇪Bochum, Germany
Ortenau Klinikum Offenburg
🇩🇪Offenburg, Germany
Hôpital Purpan
🇫🇷Toulouse, France
Vrije Universiteit Medisch Centrum
🇳🇱Amsterdam, Netherlands
Fondazione IRCCS- Istituto Neurologico Carlo Besta
🇮🇹Milano, Italy
National Hospital Organization Hiroshima-nishi Medical Ctr.
🇯🇵Hiroshima, Japan
Yokohama City University Medical Center
🇯🇵Kanagawa, Japan
Shonan Atsugi Hospital
🇯🇵Kanagawa, Japan
Hospital de Donostia
🇪🇸San Sebastian, Pais Vasco, Spain
National Hospital Organization Chiba-East Hospital
🇯🇵Chiba, Japan
Signet Research
🇳🇿Christchurch, New Zealand
Ospedale S. Gerardo
🇮🇹Monza, Italy
Kobe University Hospital
🇯🇵Hyogo, Japan
Iwate Medical University Hospital
🇯🇵Iwate, Japan
Charite-Universitätsmedizin Berlin
🇩🇪Berlin, Germany
Clinica Neurologica
🇮🇹Roma, Italy
Kashiwado Hospital
🇯🇵Chiba, Japan
Kings College Hospital
🇬🇧London, United Kingdom
Flexivest Fourteen Research Center
🇿🇦Bellville, Western Cape, South Africa
CHUV Lausanne
🇨🇭Lausanne, VD, Switzerland
Jeroen Bosch Ziekenhuis
🇳🇱's-Hertogenbosch, Netherlands
Hospital Universitario Ramon y Cajal
🇪🇸Madrid, Spain
Royal Hallamshire Hospital
🇬🇧Sheffield, United Kingdom
Nippon Medical School Chiba Hokusoh Hospital
🇯🇵Chiba, Japan
Maebashi Red Cross Hospital
🇯🇵Gunma, Japan
Shinozuka Hospital
🇯🇵Gunma, Japan
Clinical Investigation and Research Unit (CIRU)
🇬🇧Brighton, United Kingdom
Grenoside Grange Hospital
🇬🇧Sheffield, United Kingdom
Hospital 12 de Octubre
🇪🇸Madrid, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
ORKI, enheten for radiologi
🇸🇪Uppsala, Sweden
Glasgow Memory Clinic
🇬🇧Glasgow, United Kingdom
Northampton General Hospital
🇬🇧Northampton, United Kingdom
Llandough Hospital
🇬🇧Penarth, United Kingdom
Victoria Hospital
🇬🇧Swindon, United Kingdom
The Osteoporosis and Memory Centre
🇿🇦Johannesburg, Gauteng, South Africa
Hospital de la Princesa
🇪🇸Madrid, Spain
Centro Internacional de Medicina Avanzda (CIMA)
🇪🇸Barcelona, Spain
Malmo University Hospital
🇸🇪Malmo, Sweden
Hospital del Mar
🇪🇸Barcelona, Spain
Newcastle General Hospital
🇬🇧Newcastle upon Tyne, United Kingdom
St Augustine's Medical Centre 2
🇿🇦Durban, Kwa Zulu Natal, South Africa
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
Uppsala Imanet AB
🇸🇪Uppsala, Sweden
Hospital de la Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
Akademiska Sjukhuset
🇸🇪Uppsala, Sweden
Dept. of Neurosciences Charing Cross Hospital
🇬🇧London, United Kingdom
Tergooi Ziekenhuizen
🇳🇱Hilversum, Noord Holland, Netherlands
Kennemer Gasthuis
🇳🇱Haarlem, The Netherlands, Netherlands
Catharina Ziekenhuis
🇳🇱Eindhoven, Netherlands
Medisch Centrum Leeuwarden
🇳🇱Leeuwarden, Netherlands
Erasmus MC
🇳🇱Rotterdam, Netherlands
Hollywood Hospital; Pharmacy Dept
🇦🇺Nedlands, Western Australia, Australia
McCusker Alzheimer's Research Foundation, Inc.
🇦🇺Nedlands, Western Australia, Australia
The Compounding Center
🇺🇸Phoenix, Arizona, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Massachusetts General Hosptial
🇺🇸Boston, Massachusetts, United States
Banner Alzheimer's Institute
🇺🇸Phoenix, Arizona, United States
San Francisco Clinical Research Center
🇺🇸San Francisco, California, United States
Jeffrey S. Gitt, DO, PC
🇺🇸Phoenix, Arizona, United States
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States
Boston Univeristy ADCRP
🇺🇸Boston, Massachusetts, United States
General Clincial Research Center (Infusion Location)
🇺🇸Boston, Massachusetts, United States
IDS Pharmacy (Drug Receipt). Attn:Hyesson Hong
🇺🇸Boston, Massachusetts, United States
The Ohio State University
🇺🇸Columbus, Ohio, United States
Innovative Clinical Trials
🇺🇸San Antonio, Texas, United States
Integra Clinical Research
🇺🇸San Antonio, Texas, United States
Integra Clinical Research, LLC
🇺🇸San Antonio, Texas, United States
Vista Infusions
🇺🇸San Antonio, Texas, United States
Inventive Infusion Solutions
🇺🇸San Antonio, Texas, United States
Inventive Infusions Solutions
🇺🇸San Antonio, Texas, United States
Center for Psychiatric Medicine
🇺🇸Birmingham, Alabama, United States
University of Alabama-Birmingham
🇺🇸Birmingham, Alabama, United States
UAB Clinical Research Pharmacy-Russell Clinic
🇺🇸Birmingham, Alabama, United States
Participant and Clinical Interactions Resources
🇺🇸Birmingham, Alabama, United States
Mile HIgh Research Center
🇺🇸Denver, Colorado, United States
Summit Research Network(Oregon) Inc.
🇺🇸Portland, Oregon, United States
Providence Brain Institute
🇺🇸Portland, Oregon, United States
Providence St. Vincent Medical Center
🇺🇸Portland, Oregon, United States
Sezione di Neurologia - Dipartimento di Neuroscienze
🇮🇹Ancona, Italy
Unita' Operativa C - Riabilitazione Neurologica
🇮🇹Roma, Italy
CeSI (Centro di Scienze dell'invecchiamento) -
🇮🇹Chieti, Italy
Universita degli Studi di Siena
🇮🇹Siena, Italy
Univerzitna nemocnica Bratislava
🇸🇰Bratislava, Slovakia
CLONUS
🇪🇸Palma de Mallorca, Islas Baleares, Spain
Samodzielny Publiczny Centralny Szpital Kliniczny, Katedra i Klinika
🇵🇱Warszawa, Poland
Gunma University Hospital
🇯🇵Gunma, Japan
Kobe City Hospital Org Kobe City Medical Cente West Hp
🇯🇵Hyogo, Japan
Kagawa University Hospital
🇯🇵Kagawa, Japan
Nippon Medical School Musashi Kosugi Hospital
🇯🇵Kanagawa, Japan
Rakuwakai Otowa Hospital
🇯🇵Kyoto, Japan
National Hospital Organization Maizuru Medical Center
🇯🇵Kyoto, Japan
National Hospital Organization Niigata National Hospital
🇯🇵Niigata, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
National Hospital Organization Minami-Okayama Medical Center
🇯🇵Okayama, Japan
Osaka City University Hospital
🇯🇵Osaka, Japan
Kansai Medical University Takii Hospital
🇯🇵Osaka, Japan
National HP.Org.Shizuoka Inst.Epilepsy,Neurological Disorder
🇯🇵Shizuoka, Japan
Juntendo University Hospital
🇯🇵Tokyo, Japan
Juntendo Tokyo Koto Geriatric Medical Center
🇯🇵Tokyo, Japan
Tokyo Metropolitan Health and Med. Treatment Co. Ebara Hosp
🇯🇵Tokyo, Japan
Tokyo Medical University Hospital
🇯🇵Tokyo, Japan
Tokyo Medical University Hachioji Medical Center
🇯🇵Tokyo, Japan
Centre d'Imagerie medicale de Basse Normandie
🇫🇷Caen, France
CHRU de Lille
🇫🇷Lille, France
CHU - Hopital Charles Nicolle
🇫🇷Rouen, France
CHU Toulouse - Site Casselardit
🇫🇷Toulouse, France
Especialidades Medicas LyS
🇨🇱Santiago, Chile
Landeskrankenhaus Klagenfurt
🇦🇹Klagenfurt, Austria
Ita-Suomen Yliopisto
🇫🇮Kuopio, Finland
Psicomedica Research Group
🇨🇱Santiago, Chile
Klinicki centar Srbije
🇷🇸Belgrade, Serbia
Hopitaux Universitaires de Geneve
🇨🇭Thonex-Geneva, Switzerland
Donauspital
🇦🇹Wien, Austria
Hospitais Da Universidade De Coimbra
🇵🇹Coimbra, Portugal
MAC UK Neuroscience Ltd
🇬🇧Blackpool, Lancashire, United Kingdom
National Hospital Organization Tokyo National Hospital
🇯🇵Kiyose, Tokyo, Japan
Instituto Biomedico de Investigacion A.C
🇲🇽Aguascalientes, Mexico
NZOZ "NEURO-KARD" "ILKOWSKI I PARTNERZY" Spolka Partnerska Lekarzy
🇵🇱Poznan, Poland
Hospital Santa Maria
🇵🇹Lisboa, Portugal
Institute for Cardiovascular Diseases of Vojvodina
🇷🇸Sremska Kamenica, Serbia
Panorama Psychiatry and Memory Clinic
🇿🇦Panorama, Western Cape, South Africa
Hospital Universitario Son Espases
🇪🇸Palma de Mallorca, Islas Baleares, Spain
OCA Hospital
🇲🇽Monterrey, Nuevo León, Mexico
Szpital Uniwersytecki, Oddzial Kliniczny Klinik Chorob Wewnetrznych i
🇵🇱Krakow, Poland
Oddzial Neurologiczny i Udarowy Szpital Wolski im. dr Anny Gostynskiej,
🇵🇱Warszawa, Poland
Hospital Fernando da Fonseca
🇵🇹Amadora, Portugal
Klinicki Centar Vojvodina
🇷🇸Novi Sad, Serbia
Hospital Virgen del Puerto
🇪🇸Plasencia, Caceres, Spain
Clinical Centre Kragujevac, Clinic of Psichiatry
🇷🇸Kragujevac, Serbia
Diagnostic Imaging Center
🇷🇸Sremska Kamenica, Serbia
Psychiatricka nemocnica Michalovce, n.o.
🇸🇰Michalovce, Slovakia
Hospital General Universitario de Elche
🇪🇸Elche, Alicante, Spain
Yale PET Center
🇺🇸New Haven, Connecticut, United States
Abington Neurological Assoc
🇺🇸Abington, Pennsylvania, United States
University of Pennsylvania-Penn Memory Center
🇺🇸Philadelphia, Pennsylvania, United States
Jefferson Hospital for Neuroscience
🇺🇸Philadelphia, Pennsylvania, United States
Hospital Research Unit
🇺🇸New Haven, Connecticut, United States
Investigational Drug Service
🇺🇸New Haven, Connecticut, United States
MR Research Center
🇺🇸New Haven, Connecticut, United States
Hospital Divino Valles
🇪🇸Burgos, Spain
Dedicated Clinical Research
🇺🇸Goodyear, Arizona, United States
HOPE Research Institute
🇺🇸Phoenix, Arizona, United States
Collaborative Neuroscience Network, Inc
🇺🇸Long Beach, California, United States
Associated Neurologists, PC
🇺🇸Boulder, Colorado, United States
Alzheimer's Disease Research Unit
🇺🇸New Haven, Connecticut, United States
Research Center for Clinical Studies, Inc.
🇺🇸Norwalk, Connecticut, United States
JEM Research Institute, LLC
🇺🇸Atlantis, Florida, United States
JEM Research Institute
🇺🇸Atlantis, Florida, United States
NeuroStudies.net
🇺🇸Lawrenceville, Georgia, United States
Southern Illinois University School of Medicine Department
🇺🇸Springfield, Illinois, United States
Brigham & Womens Hospital
🇺🇸Boston, Massachusetts, United States
Alzheimer's Research Corp./Merician Institute for Aging
🇺🇸Manchester, New Jersey, United States
Providence Cognitive Assessment Clinic
🇺🇸Portland, Oregon, United States
Medical University of South Carolina
🇺🇸North Charleston, South Carolina, United States
National Hospital Organization Minami-Kyoto Hospital
🇯🇵Kyoto, Japan
National Hospital Organization Matsumoto Medical Center
🇯🇵Nagano, Japan
Medisch Centrum Alkmaar
🇳🇱Alkmaar, Netherlands
Psychiatricka ambulancia
🇸🇰Bratislava, Slovakia
Vseobecna nemocnica Rimavska Sobota
🇸🇰Rimavska Sobota, Slovakia
Boithuso Caregivers
🇿🇦Johannesburg, Gauteng, South Africa
Hospital Mutua de Terrassa
🇪🇸Terrassa, Barcelona, Spain
Hospital de Cruces
🇪🇸Baracaldo, Vizcalla, Spain
Fundacio ACE Institut Catala de Neurociences Aplicades
🇪🇸Barcelona, Spain
Hospital Universitario Virgen de la Arrixaca
🇪🇸Murcia, Spain
MAC UK Neuroscience, Research Assessment Centre
🇬🇧Trafford Park, Manchester, United Kingdom
Memory Clinic Neuro-Psychologie Zentrum
🇨🇭Basel, BS, Switzerland
Pollard Park Health Centre
🇬🇧Bradford, United Kingdom
Medical Specialist of the Palm Beaches
🇺🇸Atlantis, Florida, United States
University of Kansas Medical Center
🇺🇸Kansas City, Kansas, United States